Navigation Links
BioDelivery Sciences Announces Results from Phase 3 Efficacy Study for BEMA Buprenorphine in Chronic Pain
Date:9/28/2011

the product of $500 million in annual peak sales should not change based on the delay this outcome creates, and we will continue our ongoing partnering discussions in earnest, including the sharing of these results, which we believe should be viewed positively.  We anticipate our partner discussions will also aid us in refining the design for our next study.  In summary, we firmly believe that the future of BEMA Buprenorphine for chronic pain, and for our company in general remains bright."

"Moreover, our stockholders should not lose sight of our equally exciting BEMA Buprenorphine/Naloxone product for the treatment of opioid dependence.  We plan to initiate our pivotal bioequivalence trial by the end of this year with data expected in the first quarter of 2012.  It is important to remember that BDSI growth potential is not dependent on one product and that we will continue to develop our promising product opportunities," concluded Dr. Sirgo.

About the Phase 3 BEMA Buprenorphine Trial

The Phase 3 clinical trial (BUP-301) was an enriched-enrollment, double-blind, randomized withdrawal study to evaluate the efficacy and safety of BEMA Buprenorphine in the treatment of chronic lower back pain in opioid naive and experienced patients.  A total of 334 patients enrolled in the trial.  Patients who titrated to an effective and tolerated dose were randomized to either continue on that dose of BEMA Buprenorphine, or be randomized to placebo (BEMA film with no active drug), with treatment continuing for 12 weeks.  The primary efficacy endpoint was the difference in pain intensity scores (on a numerical rating scale of 0 to 11) from the time patients were randomized to receive either BEMA Buprenorphine or placebo to week twelve.

Conference Call Information

BioDelivery Sciences will hold a webcast on Thursday, September 29, at 8:30 AM Eastern Time to discuss the results of this study.  In
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
5. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
6. Derma Sciences Reports Second Quarter 2008 Results
7. Advanced Life Sciences Announces Second Quarter 2008 Financial Results
8. The Michigan Life Sciences Pipeline Adds More Resources On Its Website
9. Milestone Biosciences, LLC Further Strengthens Executive Management Team
10. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
11. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project ... the legal requirements around using controlled substances in pharmaceutical ... As their international operations expand and become increasingly complex, ... as a result of the first phase of the ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 ... technologies such as the Bioruptor® and complete solutions ... system for chromatin immunoprecipitation, alleviating the need for ... and controls needed for ChIP of histones or ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:1/22/2015)... GenoSpace , a precision medicine software company that has developed ... of genomic, imaging and other biomedical data in research and ... , CEO of Aspera, an IBM Company, to its board ... "We are pleased to welcome Michelle ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4GenoSpace Expands Board with Appointment of Michelle Munson 2
... Jan. 9, 2012 diaDexus, Inc. (OTC Bulletin ... vitro diagnostic products addressing unmet needs in cardiovascular ... approximately $4.9 million, up 48% from the prior ... 2011 revenue to $16.4 million, up 39% over ...
...   Sigma-Aldrich Corporation (NASDAQ: ... announced it has signed an agreement to acquire BioReliance Holdings, ... Avista Capital Partners for $350 million in cash.  The acquisition ... is expected to close in the first quarter of 2012.  ...
... 2012  Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX ), ... of drugs for the treatment of human viral diseases, ... clinical trial of IDX184, the Company,s lead product candidate ... IDX184, a pan-genotypic oral nucleotide polymerase inhibitor, has demonstrated ...
Cached Biology Technology:diaDexus, Inc. Pre-Announces 2011 Q4, YE Revenue and 2012 Guidance 2diaDexus, Inc. Pre-Announces 2011 Q4, YE Revenue and 2012 Guidance 3Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 2Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 3Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 4Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184 2Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184 3Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184 4Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184 5
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
(Date:1/22/2015)... has launched its new NXG series of time clocks with ... higher standard for collecting attendance and labor data and complements ... touch screen interface and seamless connection to cloud-based iSolved, the ... for the small to mid-size employer. The G2 ...
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 Holiday Season may ... Acuity Market Intelligence reports that the long anticipated floodgates ... that intensifying demand for smart phones, tablets, and wearable ... market of 2.5 billion users with nearly 4.8 billion ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Infinisource's NXG series sets new time clock standard 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2
... production of a protein called vasostatin may prove a promising ... of print in Gut. , Pancreatic cancer is the fifth ... is extremely difficult to treat. Only 3% of affected patients ... that has remained static for the past three decades. , ...
... scientists for the first time has detected a memory ... a single, new stimulus. The research, done with honeybees ... living brain and explore short-term memory as never before, ... on the report who is currently a postdoctoral research ...
... among American men. It is estimated ... six males will develop the disease during his lifetime. However, promising new ... One of the most innovative of these treatments is robotic-assisted laparoscopic prostatectomy ... one of only ...
Cached Biology News:Gene therapy potential for treatment of pancreatic cancer 2Team led by Carnegie Mellon University scientist finds first evidence of a living memory trace 2Team led by Carnegie Mellon University scientist finds first evidence of a living memory trace 3Penn Surgeons Use Completely Robotic Surgery to Successfully Treat Prostate Cancer 2Penn Surgeons Use Completely Robotic Surgery to Successfully Treat Prostate Cancer 3
...
...
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... is designed to deparaffinize and perform Heat ... paraffin-embedded tissue sections mounted on glass microscope ... paraffin at the high temperature used in ... of the paraffin by detergent. Formaldehyde fixation ...
Biology Products: